Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

by Pedro Nazareth Aguiar Jr., Pui San Tan, Sarah Simko, Carmelia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro del Giglio, Gilberto de Lima Lopes Jr